Patent Settlements Blocking Authorized Generics May Get Supreme Court Review
This article was originally published in The Pink Sheet Daily
GlaxoSmithKline and Teva hope that lower court disagreements, if not exactly a circuit split, will be enough to get high court to revisit its Actavis decision.
You may also be interested in...
Global settlement resolves charges against Teva in three pending FTC antitrust suits and expands terms of 2015 consent decree.
Justices rule FTC can make its case in court that Solvay’s reverse payment settlement with Actavis and two other generic companies was anticompetitive; GPhA says opinion could decrease the number of patent challenges by generic manufacturers, but Actavis pledges to continue defending these deals.
Existing emergency use authorizations to remain in effect and FDA may continue to issue new ones. Pfizer and Merck are moving to transition Paxlovid and Lagevrio to full approval as FDA allows prescribing without a positive COVID test first.